Investigation of a pMDI system containing chitosan microspheres and P134a

Williams, Robert O.; Barron, Melisa K.; Alonso, María José; Remuñán‐López, Carmen

doi:10.1016/s0378-5173(98)00266-x

Cited by 43 publications

(15 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chitosan (CS) is a biocompatible and biodegradable natural polymer used in nasal spray formulations (40), and a potential candidate carrier for inhalation therapy (41). CS is a polysaccharide comprised of glucosamine and N-acetylglucosamine.…”

Section: Design and Synthesis Of The Particle Shellmentioning

confidence: 99%

Core–shell Particles for the Dispersion of Small Polar Drugs and Biomolecules in Hydrofluoroalkane Propellants

Bharatwaj

Panyam

et al. 2007

Pharm Res

View full text Add to dashboard Cite

show abstract

Section: Design and Synthesis Of The Particle Shellmentioning

confidence: 99%

Core–shell Particles for the Dispersion of Small Polar Drugs and Biomolecules in Hydrofluoroalkane Propellants

Bharatwaj

Panyam

et al. 2007

Pharm Res

View full text Add to dashboard Cite

show abstract

“…Chitosan-microspheres have been formulated in order to be spread out into hydrofluoroalkanes (HFAs), novel propellant used for pressurized inhalers having a respirable fraction ranging up to 18% (Williams et al 2000). …”

Section: Significance Of Nanotechnology By Pulmonary Routementioning

confidence: 99%

From Fluorescence Nanoscopy to Nanoscopic Medicine

Peters

2008

Nanomedicine

117

View full text Add to dashboard Cite

The purpose of this review is to discuss the impact of nanocarriers administered by pulmonary route to treat and to diagnose respiratory and non respiratory diseases. Indeed, during the past 10 years, the removal of chlorofluorocarbon propellants from industrial and household products intended for the pulmonary route has lead to the developments of new alternative products. Amongst these ones, on one hand, a lot of attention has been focused to improve the bioavailability of marketed drugs intended for respiratory diseases and to develop new concepts for pulmonary administration of drugs and, on the other hand, to use the pulmonary route to administer drugs for systemic diseases. This has led to some marketed products through the last decade. Although the introduction of nanotechnology permitted to step over numerous problems and to improve the bioavailability of drugs, there are, however, unresolved delivery problems to be still addressed. These scientific and industrial innovations and challenges are discussed along this review together with an analysis of the current situation concerning the industrial developments.

show abstract

“…The new MDI systems utilize hydrofluoroalkanes (HFAs) as propellants. Through formulation optimization, these systems can provide advantages over the chlorofluorocarbon‐based MDIs,13 such as enhanced deep lung deposition, the ability to deliver drug doses above 1 mg, and compatibility with proteins and peptides 14–16…”

Section: Introductionmentioning

confidence: 99%